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Hallmarks ofautoimmune diseases such as SLE are hypergammaglobulinemia,
the production of autoantibodies, and elevated levels of circulating immune com-
plexes . Several mouse strains are used as models ofSLE (see reference 1 for review),
including NZB, NZB/NZW F t , MRL/lpr, and BXSB . In human and murine SLE,
there is frequently a.pronounced inhibition ofmacrophage binding and phagocy-
tosis of IgG-sensitized erythrocytes and immune complexes (2-4) . One possible reason
for this inhibition is the downmodulation of the macrophage FcyR after binding
ofimmune complexes . An alternate explanation for the inhibition of FcyR func-
tion might be the binding of anti-FcyR autoantibody to the macrophage FcyR .
In this study, we have used a recombinant truncated FcyR (tFcyR) t to screen mu-
rine sera and mAbs for naturally occurring anti-FcyR antibody. The tFcyR is de-
rived from murine FcyRIIf, and consists of the two external Ig-like domains ofmuFc-
yRIIa, but lacks the transmembrane and cytoplasmic domains of the receptor (5) .
We report here the presence and characterization of anti-FcyR antibodies in sera
ofsome mice genetically prone to autoimmune diseases and anti-FcyR hybridomas
derived from NZB and motheaten (me") mice .
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AUTOIMMUNE MICE MAKE ANTI-Fcy
RECEPTOR ANTIBODIES
Materials and Methods
mAbs and Sera.
￿
The mAbs that we screened for anti-FcyR activity were derived from fu-
sions with spleen cells from old NZB mice or young NZB mice after stimulation with LPS
(6) . Other hybridomas screened were from unstimulated viable me' mice (7) . The IgM
mAbs were all purified by affinity chromatography on an anti-tc IgG-Sepharose column
and were eluted from the column with 0 .1 M glycine HCI, pH 2.3 . Samples of sera from
NZB, NZB/NZW F,, MRL/lpr, and BXSB mice were kindly given to us by Dr. Argyris
Theofilopoulos (Scripps Clinic, La Jolla, CA) . Sera from me', tightskin mouse (TSK),
C57B1.6pa/pa, and C58/J were obtained from animals purchased from The Jackson Labora-
tory (Bar Harbor, ME). Anti-DNP hybridomas DHK109 .3 (IgGl) and DHK10.12 (IgG2b)
were a gift from Dr. Milton Schlessinger (Washington University Medical School, St . Louis,
MO) ; anti-DNP hybridomas U7.6 (IgGl) and U7-27 (IgG2a) were a gift from Dr. Zelig Es-
char (Weitzmann Institute, Rehovot, Israel) .
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tFcyR.
￿
tFcyR was purified by affinity chromatography on an IgG-Sepharose column from
conditioned medium of the D1959 CHO cell line as previously described (5). The purified
protein in PBS was denatured, for some experiments, by reduction with 10 mM dithiothre-
itol at 56°C followed by alkylation with 25 mM iodoacetamide. The alkylated receptor was
then dialyzed against PBS.
ELISA.
￿
Anti-FcyR Ig was assayed by ELISA. Flat-bottomed microtiter plates (Immu-
lon-2; Dynatech Laboratories Inc., Alexandria, VA) were coated overnight with either native
or denatured FcyR (2 .5,ug/ml in 0.1 M NaC03 buffer, pH 9.5) and then blocked with 1.0%
NP-40 in PBS. FcyR-coated plates were then incubated with serum samples diluted in 1°Jo
NP-40/PBS. Anti-FcyR antibodies were detected by sequential addition of biotinylated goat
F(ab')2 anti-mouse IgM or biotinylated goat anti-mouse IgG (0 .5 p,g/ml) (Kirkegaard &
Perry Laboratories, Inc., Gaithersburg, MD) and streptavidin-horseradish peroxidase (0.5
Ftg/ml) (Kirkegaard & Perry Laboratories, Inc.), and developed as described previously (5).
The rat mAb 2AG2 was detected using a horseradish peroxidase goat anti-rat IgG reagent
(Kirkegaard & Perry Laboratories, Inc.). For competition assays, protocols were similar ex-
cept that the mAbs were incubated (1 h, room temperature) with serial dilutions of either
native tFcyR or mAb 2AG2 before they were adsorbed onto the tFcyRcoated plates. All ex-
periments were done in triplicate and the variation between the triplicates was <10%.
Binding Assays.
￿
Binding of mAbs to cells was determined by FAGS analysis. J774 cells
(a macrophage-like cell line) were incubated in suspension (0.5-1 .0 x 106 in 100 Al) with
mAbs directly conjugated to FITC, sera, or affinity-purified Ig diluted in PBS containing
1% BSA (1 h, VC), and washed with PBS-1% BSA. For experiments with mouse sera or
affinity-purified mouse Ig, bound Ig was visualized after incubation (1 h, 4°C) with either
biotinylated goat F(ab')2 anti-mouse IgM or biotinylated goat anti-mouse IgG followed by
streptavidin-FITC (Kirkegaard and Perry Laboratories, Inc.) used at manufacturer's recom-
mended dilution. After fixation in 1% neutral buffered formalin, the cells were analyzed by
flow cytometry on a Epics cytofluorograph (Coulter Electronics Inc., Hialeah, FL) with three
decades ofamplification. Mean fluorescence peak channels were converted to relative fluores-
cence to compare the samples.
Affinity Chromatography.
￿
A tFcyR affinity column was made by coupling 4 mg of tFcyR to
1 ml of Reactigel-HW65 (Pierce Chemical Co., Rockford, IL) according to manufacturer's
instructions. The efficiency of coupling was >90%. Serum (0.6 ml) was passed over a 3 x
100-mm column, which was then washed with 0.1 M NaP04, pH 7 .4. Bound Ig was eluted
with 0.1 M glycine HCl, pH 2 .3, neutralized with .1 vol of 1 M Tris HCl, pH 8.5, and the
amount of IgM and IgG was analyzed by ELISA with IgM and IgG standards.
Inhibition ofBinding Immune Complexes by Anti-FcyR mAbs and Mouse Sera.
￿
10 mg BSA in 1
ml of PBS was incubated with 1 mg trinitrobenzene sulfonic acid to introduce the TNP moiety.
To remove the uncoupled hapten, the mixture was passed over a small Sephadex G25 column.
The molar ratio of BSA/TNP was 1 :20 (8). Anti-DNP antibody U7.6 (IgGl) was conjugated
with FITC, and an optimum ratio of FITC-U7 .6/DNP2o-BSA for binding of immune com-
plexes to J774 cells was determined by FACS. In experiments here, we used a 4:1 ratio of
FITC-U7.6/DNP2o-BSA. Inhibition of the binding of FITC-immune complexes to J774 cells
by anti-FcyR antibodies and sera from different mouse strains was examined by FACS. J774
cells were preincubated (1 h, room temperature) with dilutions of test sera or mAbs, washed,
and incubated with the FITC-immune complexes (1 h, 4°C).
Results
Detection of Anti-FcyR Antibodies in Mouse Serum.
￿
To detect the presence of anti-
Fc-yR antibodies in sera, we developed an ELISA using microtiterplates coated with
a recombinant truncated murine FcyRII0 secreted by CHO cells (5). The protein
consists solely ofthe two Ig-like extracellulardomains. Since the native tFcyR binds
IgG, tFcyRused to coat the ELISA plates was reduced and alkylated, a procedure
that destroys the epitope recognized by mAb 2AG2 and also ablates the binding
of immune complexes.We found that several strains of mice, most notably NZB, NZB/NZW FI, me",
and TSK, have readily detectable anti-FcyR IgM in their serum (Fig . 1). The titer
of anti-FcyR antibody for TSK, NZB/NZW F1, and, to a lesser degree, MRL/lpr
mice, increased with the age of the mice . Although in this set of sera the titers of
anti-FcyRIgM in 3-mo-old vs . 8-mo-old NZB mice were not significantly different
(Fig . 1), a second set of sera from NZB mice showed a clear correlation between
anti-FcyR IgM titer and age (Fig . 2). Surprisingly, the older BXSB males, which
develop a severe form of SLE, did not have a significant level of anti-FcyR IgM .
Titration oftwo serum samplesfrom autoimmune mice and a normal C58/Jserum
for anti-FcyR IgM on tFcyR-coated and control microtiter plates is shown in Fig .
3 . The C58/J serum gives no signal either on tFcyR or control wells at anydilution .
Although the autoimmune sera show a slightly higher background than the C58/J
serum, there is a >10-fold difference between the FFoyR-coated and the control wells.
We chose as controls C58/J mice since old animals produce small amounts of anti-
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FIGURE 1 .
￿
Anti-FcyRIgM in
sera of autoimmune mice . In-
dividual serum samples diluted
1 :100 in 1% NP-40/PBS were
assayed on microtiter plates
coated with reduced and alkyl-
ated FFcyR, and developed with
biotinylated anti-IgM antibody
as described in Materials and
Methods .
FIGURE 2 .
￿
A set ofsera from NZB mice ofdifferent ages
was assayed for anti-FcyR IgM titer as described in Fig. 1 .1584 ANTI-Fc., RECEPTOR ANTIBODIES IN SERA OF AUTOIMMUNE MICE
DNA antibodies but do not develop a lupus-like disease. The IgM levels of the
autoimmune mice areat most threefold higher than levels ofnormal mice (1). There-
fore, results in Fig. 3 could not be due to elevated levels of IgM in sera of autoim-
mune mice compared with normal controls. Toexclude thepossibilitythat thebinding
ofimmune complexesin the serum ofmice with autoimmune disease mightexplain
these results, we centrifuged normal and autoimmune sera in an airfuge (Beckman
Instruments) for 20 min at 100,000g. The resultant decrease of30-50% in the titer
ofanti-FcyR IgM is probably due to sedimentation ofIgM in the short pathlength
of the airfuge rotor (data not shown).
Mice that make IgM anti-FcyR antibody also make IgG anti-FcyR antibody, a
factthat indicatesthattheresponseisnotlimitedto IgM. There is apositivecorrela-
tion between titers ofIgM anti-FcyRantibody and IgG anti-FcyR antibody in in-
dividual sera (Fig. 4). Internal IgM and IgG controls confirm the IgG and IgM
specificity of the reagents used in these assays.
Affinity Purification of anti-FcyR Antibody.
￿
To determine with more precision the
levels of anti-FcyRIg and to confirm the ELISA data indicating that there is little
anti-FcyR Ig in normal mouse serum, we subjected serum pooled from 8-mo-old
NZB female and 12-mo-old C58/J female mice to affinity chromatography on a
FFcyRReactigel-HW65 column. After elution with 0.1 M glycine HCI, pH 2.3, the
eluate was analyzed for IgM and IgG by ELISA with appropriate standards. We
found 16 Ftg/ml of anti-FcyR IgM in pooled serum from aged NZB female mice,
but no IgM was eluted after affinity chromatography pool ofserum from C58/J fe-
male mice. The eluted material from the tFcyR column was also assayed for IgG.
Eluates from boththe C58/J and the NZB serum samples contained90ttg ofIgG/ml
of serum. However, since the FFcyRcoupled to the column was not denatured, we
interpret this as reflecting primarily bindingofIgG tothe tFcYR, and not antigenic
specificity of the IgG.
To examine the specificity of the IgG eluted from the tFcyRcolumn, we assayed
fractions on microtiter plates coated with reduced and alkylated FFyyR. IgG affinity
purified fromthe NZB serum bound tothe denatured tFeyR, and showed a decrease
inOD 495 nmwith increasing dilution. In contrast, the IgG eluted from the C58/J
serum barely exceeded the background ofthe IgG2amyeloma control, and the OD
1 /Dilution
FIGURE 3.
￿
Titration of anti-FcyR IgM. Sera
from an 8-mo-old NZB mouse (A, A); a 7-mo-
old NZB/NZW FI mouse (0, /), and a 12-mo-
old C58/J mouse (O, *)were diluted in 1% NP-
40/PBS and assayed on control microtiter plates
(A, 0, O) or plates coated with reduced and alky-
lated tFcyR (A, 0, ").
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495 nm did not vary with dilution (Fig. 5). Since the same amount of IgG was iso-
lated from the C58/J serum as from the NZB serum, we assume most of the IgG
isnonspecific. Therefore, thebindingwe detect in this experiment reflects high affinity
anti-FcyR IgG present at concentrations <2.5 Wg/ml.
In addition to binding to FcyyRcoated plates, the affinity-purified Ig from the NZB
serum bound toJ774 macrophages to a much greater extent than either affinity-
purifiedIg from C58/J serum orisotypecontrols (Table I, Fig. 6). We also examined
the staining of macrophages by serum from C58/J, NZB and me" mice. The au-
toimmune sera, but not the C58/J serum, contained IgM that bound toJ774 cells.
Surprisingly, we did not find any staining ofJ774 cells by NZB or me' sera when
the cells were stained with an anti-IgG reagent.
Anti-FcyR mAbs.
￿
Since the sera ofNZB mice had a high titer ofanti-FcyR anti-
body, we decided to screen by ELISA a panel ofmAbs from autoimmune mice (6).
Out of20 IgM mAbs from fusions with LPS-stimulated spleen cells from 3-mo-old
NZB mice, one anti-FcyRIgM, ZK2H5-3, was found; out of20 mAbs isolated from
fusions with spleen cells from unstimulated 16-mo-old NZB mice, two more IgM
mAbs, ZL37-9 and ZL173-7, were identified (Fig. 7). We found, in addition, an
anti-FcyR IgM mAb, UN40-6, from a fusion with me° mouse spleen cells (7). Fig.
7 shows the binding ofthese mAbs to native and reduced and alkylated tFcyR, as
well asthe binding ofmonomeric IgG1 and mAb 2AG2 under the same conditions.
Because IgM does not bind to FcyR, we could use native FcyRto coat ELISA plates
without fearofartifactual bindingofIgM. Wefound thatZL37-9 and ZL173-7bound
0.9
0.0
OD 495 nm (anti-IGG)
------------
5 2.5 1.25 0.62
Concentration (uG/ml)
BOROS ET AL.
￿
1585
-"- IGG1
- "- IGG2a
_.,_. IGG2b
- " C38/J IGG
- " - NZB IGG
FIGURE 5.
￿
Titration of affinity-purified IgG.
Isotype controls andaffinity-purified Ig were ad-
sorbed onto microtiter platescoated with reduced
and alkylated FFcyR, andassayed with biotinyl-
ated anti-mouse IgG. Theamount of IgGin the
protein eluted from the FFcyRcolumn from the
NZB and C58/J serum pools was assayed by
ELISA.1586 ANTI-Fcy RECEPTOR ANTIBODIES IN SERA OF AUTOIMMUNE MICE
TABLE I
Binding of Affinity-purified IgG and Sera to J774 Cells
Cells were incubated with isotype controls (5 pg/ml), with affinity-purified IgG
(2 .5 pg of IgG/ml), or with serum (1:100 dilution) diluted in PBS containing
1% BSA. The cells were stained with biotinylated reagents as described in Materi-
als and Methods . The percentage of cells that were positive was estimated by
setting the cursor so that -I% of the control without mAb were positive .
better to native tFcyR than to reducedand alkylated tFc7R, whereas ZK2H5-3 bound
equally to both forms . The 2AG2 epitope is completely inactivated by reduction
and alkylation, and the binding of IgG1 is also strongly inhibited .
We examined the avidity of binding ofthe IgM anti-FcyR mAbs to native tFcyR-
coated microtiter plates (Fig . 8) . In several experiments themaximal binding ofmAb
ZK2H5-3 was less than ZL37-9 and ZL173-7 . ZL37-14 is an IgM mAb control . ZL37-9
had the poorest avidity, -108 M -1 , while the other two have an apparentKa of 109
FIGURE 6 .
￿
FAGS analysis ofJ774 cells incubated with
Ig purified by affinity chromatography . Cells were stained
with 5 pg/ml of IgG2a (A), or 2.5 jig/ml of total IgG
isolated by affinity chromatography on a tFcyRcolumn
from either old NZB mice (B) or C58/J mice (C), and
bound IgG was visualized with biotinylated goat
anti-mouse IgGandstreptavidin-HRP as described. The
mean peak channel numberswere : (A) IgG2a, 56 ; (B)
NZB, 88 ; (C) C58/J, 61 .
Sample
Percent
Anti-IgG
positive cells
Anti-IgM
IgG1 (DHK109.3) 2.6
IgG2a (U7-27) 2.9
IgG26 (DHK10.12) 2.5
C58/J Ig (affinity purified) 8.4
NZB Ig (affinity purified) 32.2
C58/J serum (12 mo) 2.6 1 .8
NZB serum (3 mo) 1 .4 10 .8
NZB serum (8 mo) 3 .3 16 .6
me` serum (2 mo) 1 .3 19 .4E c
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M-I. This high avidity probably reflects the dense coating ofthe ELISA plates with
FcyR, which results in multivalent cooperative binding of IgM.
We examined the binding of the mAbs toJ774 cells. To eliminate uncertainties
inherent in the use ofsecond antibody reagents, we derivatized the mAbs directly
with FITC. The mAbs ZL37-9 and ZL173-7 stain murine macrophage cell lines
poorly. This probably reflects a low intrinsic affinity ofthe antibodies. ZK2H5-3
and UN40-6 stainJ774 cells intensely, but since thesemAbs haveso many specificities,
we cannot unequivocally state that the mAbs are binding to the FcyR. The posi-
tively stained population examined by fluorescence microscopy showed a surface
membrane fluorescence pattern typical of membrane antigens.
The specificity of three anti-FcyR mAbs was examined further by competition
assays with both tFcyR (Fig. 9 A) and mAb 2AG2 (Fig. 9 B) (9), which is directed
against muFcyRII. All mAbs were inhibited by tFcyR. The inhibition by mAb 2AG2
varies for the different mAbs. ZK2H5-3 is inhibited by 50-100-fold less 2AG2 IgG
than are ZL37-9 and ZL173-7. However, from these results, one cannot conclude
that the antibodies ZL37-9 and ZL173-7 recognize similar epitopes since steric hin-
drance could account for the results. The data, however, confirm the anti-FcyR
specificity of the IgM anti-FcyR mAbs.
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FIGURE 7.
￿
Binding of mAbs
to FFcyR-coated microtiter
plates. The concentrations of
mAbs used were: ZL37-9, 2.5
jug/ml; ZL173-7, 0.63 Rg/ml;
ZK2H5-3, 2.5 ag/ml; DHK-
109.3 IgGl, 10jig/ml; 2AG2, 10
wg/ml. Secondary antibodies
were specific for either mouse
IgM, mouse IgG, or rat IgG as
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FIGURE 9.
￿
Competition by tFcyR or mAb 2AG2 of the binding ofanti-FcyR mAbs to tFcyR-
coated microtiter plates. (A) Competition by tFcyR. Samples were preincubated for I h at room
temperature before assay. (B) Competition by anti-FcyR mAb 2AG2. mAb 2AG2 was added
to the wells at the start of the assay.
The 40 mAbs that we screened had been examined previously for reactivity with
a variety of autoantigens, including DNA, histones, type I-IV collagens, an IgG2a
myeloma protein, myelin basic protein, intrinsic factor, thyroglobulin, thyroid-
stimulating hormone receptor, acetyl choline receptor (AchR), transferrin, murine
bromelain-treated RBC membranes, and topoisomerase 1 (6, 7). ZL173-7, in addi-
tion to binding FcyR, also binds to procaryotic and eukaryotic dsDNA. ZL37-9 binds
to dsDNA and to fish AchR. ZK2H5-3 is a multispecific antibody, binding to his-
tones 1, 2a, 2b, and 4, AchR, and thyroglobulin. We found that the binding of the
DNA-specific mAbs ZL173-7 and ZL37-9 to DNA-coated plates is inhibitedby tFcyR
and, reciprocally, the binding to tFcyRcoated plates is inhibited by preincubation
with DNA(datanot shown). Theseobservations implythat complexes ofIgM mAbs
ZL173-7 and ZL37-9 with DNA could also bind to FcyR molecules on the plasma
membranes of phagocytes, mesangial cells, and FcyR-bearing lymphocytes. Such
multivalent complexes might have a higher avidity for FcyRs on the cells than the
IgM alone, Similarly, if mAb ZK2H5-3 formed an immune complex with nucleo-
protein (since it binds to histones), the immune complex could also bind to FcyR
molecules present on cells.
InhibitionofImmune ComplexBindingtoJ774 Cells.
￿
We have shownthat antibodies
in sera from autoimmune mice and some mAbs bind to tFcyR and also to macro-
phages. To demonstrate that the anti-FcyR antibodies could alter function, we next
looked for inhibition of immune complex binding to J774 cells (Table 11, Fig. 10).
ZL37-9 and ZL173-7, both of which bind to dsDNA, significantly inhibited immune
complex bindingto macrophages. ZL37-9 inhibits immune complex binding better
than does ZL173-7, although the former binds with lower avidity to tFcyR-coated
microtiter wells. ZK2H5-3 and UN40-6, although they bind far better to macro-
phages (Table III), are poorer inhibitors than either of the two anti-FcyR mAbs with
DNA specificity.
Sera from old female NZB mice inhibitbinding of immune complexes. The inhi-
bition is apparent even at a dilution of 1:400 (Fig. 10, B, C, and D). The me" sera
inhibited even more strongly than the NZB serum (Fig. 10, F, G, and H). In con-
trast, a 1:100 dilution of C58/J serum had no effect on the binding of immune com-
plexes to macrophages (Fig. 10 E) .BOROS ET AL.
TABLE II
Inhibition of Immune Comlblex Binding to J774 Cells
J774 cells were preincubated for 1 h at room temperature with mAbs diluted
in PBS-1% BSA, washed, and incubated with FITC-U7.6/DNP2o/H/BSA
complexes (20 Wg/ml U7 .6, 5 pg/ml DNP2o/H/BSA) at 4°C for 1 h, washed,
and fixed.
' UN40-6 data comes from a different experiment in which the mean fluores-
cence peak channel forJ774 cells incubated with immune complexes was 140.
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Discussion
Mice that areused as models forSLE make autoantibodies against many different
antigens (see reference 1 for review). Autoantibodies directed against specific pro-
teins have been identified as pathologic agents in several diseases, including cyclic
amegakaryocytic thrombocytopenia (blockade ofgranulocyte/macrophage-CSF ac-
tion) (10), vasculitis (antibody to vascular endothelial antigens) (11), autoimmune
hemolytic anemia in NZB mice (12), acquired angioedema (anti-Cl esterase inhib-
itor) (13), myasthenia gravis (14), and Graves' disease (15). This report identifies the
presence, in the sera of several inbred strainsprone to autoimmune diseases, ofboth
IgG andIgM antibody directed against the external Ig-like domains ofFcyRIl. These
antibodies were identified by an ELISA in which the plates were coated with either
a recombinant tFcyRII, consisting of the external Ig-like domains, or reduced and
alkylated tFcyRII. We believe that the recombinant tFcyR is auseful probe to screen
for anti-FcyR autoantibody since the recombinant protein is glycosylated, bindsIgG,
and bears epitopes recognized by a variety ofmonoclonal murine anti-FcyR reagents
(5, and unpublished results). Rabbit antisera elicited by the tFcyR immunoblot and
immunoprecipitate murine FcyR and will stain murine FcyRbearing cells brightly
(data not shown).
Completing
mAbs Concentration
pglmt
Mean
fluorescence
peak channel Inhibition
Control J774 cells
with complexes 158 -
ZK2H6-2 5 155 6.1
1 156 4.4
0.2 160 -6.8
ZL37-9 5 106 75.3
1 116 67.5
0.2 133 48.2
ZL173-7 5 109 73.2
1 135 55.7
0 .2 160 -6.7
ZK2H5-3 5 99 79.5
1 151 16.4
0.2 163 - 15.4
UN40-6' 5 110 54.8
1 133 15.8
0.2 130 22 .51590 ANTI-Fc y RECEPTOR ANTIBODIES IN SERA OF AUTOIMMUNE MICE
To eliminate possible artifacts due to binding of IgG or immune complexes in
the ELISA of murine sera, we coated the microtiter plates with tFcyR that hadbeen
inactivated by reduction and alkylation. The presence of anti-FcyR IgM and IgG
in sera from autoimmune mice was readily detectable at dilutions from 1:100 to
1 :300 in the ELISA . There was a positive correlation between the levels of anti-Fc yR
IgM and IgG found in the sera . However, the titer of anti-FcyR antibodies varied
considerably among the different autoimmune strains . NZB, NZB/NZW Ft, TSK,
and me" mice had high titers of anti-FcyR IgM that increased with age for the first
three strains of mice . Young MRL/Ipr had no anti-FcyR activity, but old MRL/Ipr
TABLE III
Binding of IgM mAbs to j774 Cells
FIGURE 10.
￿
Inhibition of im-
mune complex binding toJ774
cells by mouse sera . (A) The
binding of immune complexes
to cells incubated in PBS/1%
BSA, Cells were preincubated
with 1:100, 1:200, and 1 :400 di-
lutions of6-mo-old femaleNZB
mice sera(B, C, and D) ; 1 :100,
1 :400, and 1:800 dilutions of2-
mo-old me" mice sera (F, G,
and H); and a 1 :100 dilution of
C58/J serum (E). Mean peak
channels were : A, 158; B, 80 ; C,
135 ; D, 149 ; E, 156; F, 81 ; G,
126 ; H, 155 . Relative to the con-
trol inA, thesecorrespond to the
following inhibitions: B, 88% ;
C,46% ;D,21% ;E,2.7% ; F,
87% ; G, 57% ; H, 7.8% .
Cell were stained with rnAbs (5 ug/ml) (6, 7) as described and analyzed by FACS.
mAb Specificity
Mean
fluorescence
peak channel
Control 106
unstained cells
ZL37-9 FcyR, DNA, AchR 108
ZL173-7 FcyR, DNA 108
ZK2H5-3 FcyR, histones, AchR, thyroglobulin 141
UN40-6 FcyR, thyroglobulin, Sm, transferrin, 199
myelin basic protein, IgG, RBC,
thymocytesBOROS ET AL.
￿
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exhibited modest levels of anti-FcyR antibodies. BXSB mice, including old males
that have severe SLE, do not make anti-FcyR Ig.
To quantify the amount ofanti-FcyR in autoimmune mice and to confirm its ab-
sence in sera ofnormal mice, weperformed affinity chromatography ofserum from
both groups on a column coupled with tFcyR. The amount of anti-FcyR IgM in
pooled sera from old NZB female mice was 16 ug/ml serum, N2% ofthe total IgM.
Therewas no IgM recovered after affinity chromatographyofserum from oldC58/J
mice. The purified NZB anti-FcyR IgM was of low avidity. We could not detect
binding to tFcyR-coated plates or toJ774 cells at 0.2 ug/ml IgM (data not shown).
However, the,IgG fraction of the purified material bound well to FcyR on macro-
phages and bound totFcyR-coated plates. Sincewe purified the Igon a native tFc-YR
column, we do not know the absolute amount of high affinity anti-FcyR IgG.
We also examined the bindingofIgM and IgG in autoimmune and control sera
toJ774 cells. IgM, but not IgG, from serum ofautoimmune mice with high titers
ofanti-FcyR Ig bound to mouse macrophages. This paradoxical result may be due
to occupation ofthe binding site ofhigh affinity anti-FcyR IgG with soluble FcyR,
which is present in seraofmice and elevated in mice infected with schistosomes (16,
17). Results of Pure et al. (16) suggest that a major source ofserum FcyR may be
released from activated B cells, and autoimmune mice might thus be expected to
have high serum FcyR levels. The soluble FcyR level in normal mouse serum is -6 x
10-8 M (15), which would be sufficient to neutralize ti1 lAg/ml ofhigh avidity anti-
FcyR IgG in serum.
Russell and Steinberg (3) have examined the binding and phagocytosis of IgG-
sensitized erythrocytes (EIgG) by residentperitoneal macrophagesisolated from SLE-
prone mice. NZB, NZB/NZW F,, and MRL/lpr mice all had profound defects in
both binding and phagocytosis of EIgG relative to control inbred mice. The FC-yR-
defect was notreversible byculturein vitro nor by strippingwith pronase (18). How-
ever, there is no intrinsicdefect in themacrophages, since macrophages derived from
bone marrow ofautoimmune animals, orperitonealmacrophages elicited by inflam-
matory agents such as thioglycollate or Corynebacterium parvum, showed normal binding
and phagocytosis of EIgG (18). There is clear evidence that in vitro culture ofmac-
rophages on immune complex-coated surfaces results in downmodulation of FcyR
function (19). Thus, the thesis that the FcyR defect in autoimmune mice is due to
immune complexes downmodulating the FcyR is reasonable.
We would like to suggest, however, that anti-FcyRautoantibodies rather than im-
mune complexes, per se, are responsiblefor inhibition ofFcyR function in vivo. We
find high levels of anti-FcyR Ig in NZB, NZB/NZW F1, TSK, and me° mice, and
somewhat elevated levels ofanti-FcyRin old MRL/lpr mice, all ofwhich have im-
paired FcyR function. Male BXSB mice, which have a severe form of SLE, show
normal macrophage binding and phagocytosis ofEIgG (3), and we find that these
mice have no anti-FcyR Ig. The compromised FcyR function seen in other autoim-
mune strains may be related to the presence ofanti-FcyR antibody, or immune com-
plexes containing anti-FcyR IgM or IgG. In agreement with this thesis, we found
that serum from old NZB and me" mice dramatically inhibited binding of soluble
immunecomplexes, whereas the C58/J serumhad no effect. We showthat IgMfrom
NZB and me" mice binds toJ774 cells, but did not find binding of IgG from the
same sera to the cells. We therefore believe that the inhibition ofFcyR function we1592 ANTI-Fcy RECEPTOR ANTIBODIES IN SERA OF AUTOIMMUNE MICE
observed withthesesera isnotdue to IgGimmune complex bindingbut tothebinding
of IgM antibody with anti-FcyR specificity.
The anti-FcyRIgM mAbs that we identified by screening IgM NZB hybridomas
(6, 7) were multispecific. Out ofa total of40 hybridomas, we found three anti-FcyR
IgM mAbs. Two of these, ZL-37 and ZL-173, also had anti-DNA specificity, and
a third, 2K2H5, was directed against a variety ofantigens, including histones, ace-
tylcholine receptor, and thyroglobulin. A fourth anti-FcyR IgM, UN40-6, from a
hybridoma panel made from me°, was directed against a variety of antigens, in-
cluding thyroglobulin, Sm antigen, transferrin, myelin basic protein, and IgG2a(7).
The isolation of IgM antibody with diverse specificities has been reported previ-
ously (see reference 20 for review), and is related either to similar conformation
of the disparate antigens or to multiple binding sites oflow affinity within the IgM
molecule. Polyspecificity has also been reported in some IgG mAbs. An IgG anti-
DNA mAb has been shown to bind to vimentin (21) and another IgG2b anti-DNA
mAb was found to bind to renal mesangium and vascular endothelium (22), which
resulted in an increase in albumin permeability in perfused rat kidneys.
In spite of an avidity for binding of the anti-FcyR mAbs to tFcy-coated micro-
titer plates of 10$-109 M-1, we believe that the intrinsic affinity of the mAb binding
site for FcyRofZL37-9 and ZL173-7 is low because these mAbs do not stain FcyR
bearing cells. Because the FcyR density on the cells is low compared with the tFcyR-
coated ELISA plates, themAbs donotbindwith sufficient avidityto givegood staining
after washing. ZK25-3 and UN40-6 stain macrophages very well, but since these
antibodies have so many specificities, we cannot be sure that the primary antigen
recognized on the macrophage is FcTRII. However, the apparentavidity ofanti FcyR
antibody could be greatly enhanced in vivo if the anti-FcyR IgM were to form a
complex with other antigens, such as nucleoprotein coated with histones or DNA,
both ofwhichoffer multiple epitopes toform largecomplexes. Thehigh avidity anti-
FcyR IgG we have isolated by affinity chromatography might by itself bind to and
trigger FcyR-bearing cells.
Although ZL37-9 and ZL173-7 do not stain cells effectively, either using directly
fluoresceinated antibody (Table II) or anti-IgM reagents (data not shown), they do
inhibit immune complex binding toJ774 macrophages. ZL37-9 and ZL173-7 may
selectively (since IgM is pentamer) bind to a small proportion ofcell surface FcyRs
that areaggregated orpatched, and to which immunecomplexespreferentiallybind.
Alternatively, since the J774 cells were preincubated for 1 h at room temperature
with the anti-FcyR mAbs, the anti-FcyRIgM might trigger the internalization of
the FcyR.
The binding of immune complexes to FcyR on macrophages, neutrophils, and
NK cells results in the activation of phagocytic mechanisms, elaboration of toxic
metabolites ofoxygen, release ofprostaglandins and leukotrienes, and the synthesis
ofcytokines such as TNF, IFN-'Y, and IL-2 by NK cells (23). The mesangial cell,
which expresses FcyR (24, 25), might also be activated by immune complexes or
anti-FcyR antibody. Stimulation of these receptors leads to release of platelet-
activating factor, prostaglandin A2, H202, and enhanced secretion ofIL-1 (26), all
ofwhich could contribute to kidney pathology seen in SLE. The anti-FcyR anti-
bodies we describe heremay playarole intriggeringthese responses. Otherprelimi-
nary experiments show that 2K2H5 and UN40-6, when adsorbed to plastic, triggerBOROS ET AL.
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an oxidative burst from murine peritoneal macrophages elicited with thioglycollate
medium (data not shown).
The impaired FcyR function in the autoimmune mice has also been seen in pa-
tients with SLE, as well as otherautoimmune diseases such as rheumatoid arthritis
and Sjogren's syndrome (4, 27). It is possible that one component in the slow clear-
ance of immune complexes seen in lupus patients and patients with other autoim-
mune diseases isthe presence ofanti-FcyR antibody. The receptor that plays apre-
dominant role in clearanceoflarge immunecomplexes is FcyRIII orCD16. Blockade
of FcyRIII in chimpanzees with the anti-FcyRIII mAb 3G8 or its Fab fragment
resulted in a 20-foldincreasein clearance timefor IgG-sensitized chimpanzee erythro-
cytes (28). Antibody against FcyRIII allotypes NA1 and NA2 has been associated
with juvenile neutropenia (29, 30), and anti-FcyRIII antibody has also been
identified in sera ofpatients with SLE (31). The role that the anti-FcyR Ig we have
detected in the autoimmune mice and that is present in sera of patients with SLE
(31) plays in the pathology of the diseases remains to be established.
Summary
We demonstrate, using a recombinant truncated FcyRI1 molecule as a probe, the
presence of anti-FcyR antibodies in several strains of autoimmune mice. Affinity
chromatography on a truncated FcyR column of pooled sera from aged NZB fe-
males resulted in isolation of 16,ug ofIgM per ml ofserum, -2% ofthe total IgM;
no anti-FcyR IgM was found in sera from C58/J mice. Mice with high titers ofanti-
FcyRIgM also had anti-FcyRIgG. Affinity-purified anti-FcyRIgG bound to FcyR
bearing cells. A good correlation was found between the presence of anti-FcyRIg
and impaired phagocytosis of immune complexes in autoimmune strains such as
NZB or NZB/NZW F,. Sera with high titers of anti-FcyR Ig from NZB and
motheaten miceinhibited the binding ofsoluble immune complexes. Furthermore,
BXSB, alupus-prone mouse strain that does not produceanti-FcyR Ig, shows normal
macrophage binding and phagocytosis of immune complexes. A set of four IgM
mAbs that bind to FcyR was identified. These antibodies were polyspecific; some
were directed against DNA, and others recognized a wide variety of antigens in-
cluding histones, thyroglobulin, and transferrin, but all anti-FcyR IgM antibodies
effectively inhibited the binding of IgGl anti-DNP/DNP2oBSA complexes toJ774
macrophages. The role ofanti-FcyR Ig in autoimmunity remains to be established.
It may act to crosslink and activate FcyRs on neutrophils, macrophages, NK, and
mesangial cells, or it may desensitize FcyR function of FcyRbearing cells.
We thank Zhengxing Qu for his assistance and generous help in making FFcyR, and Andy
Pizzimenti for assistance with flow cytometry. Weare indebted toDr. Argyris Theofilopoulos
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